A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
The purpose of this study is to test the safety of the study drugs, pembrolizumab/MK-3475 in combination with Bacillus Calmette-Guerin (BCG) and see how well pembrolizumab in combination with BCG works compared to BCG alone.
High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that has continued or returned following BCG induction.
Must have a confirmed diagnosis of bladder cancer, must have been treated with one course of BCG induction therapy and have persistent or recurrent cancer. Must have also undergone cystoscopy/ transurethral resection of bladder tumor (TURBT) to remove all resectable disease.
18 - 120
Healthy Volunteers Needed
Duration of Participation
Up to five years
Merck Sharp & Dohme Corp